Xtant Medical Holdings, Inc. (XTNT)
| Market Cap | 58.91M -34.0% |
| Revenue (ttm) | 121.91M -0.3% |
| Net Income | 1.83M |
| EPS | 0.01 |
| Shares Out | 140.26M |
| PE Ratio | 38.17 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 112,836 |
| Open | 0.4090 |
| Previous Close | 0.3900 |
| Day's Range | 0.3905 - 0.4400 |
| 52-Week Range | 0.3887 - 0.9500 |
| Beta | -0.16 |
| Analysts | Strong Buy |
| Price Target | 1.23 (+192.86%) |
| Earnings Date | Aug 11, 2026 |
About XTNT
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFact... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for XTNT stock is "Strong Buy." The 12-month stock price target is $1.23, which is an increase of 192.86% from the latest price.
News
Xtant Medical Holdings Proxy statement: Proxy filing
Xtant Medical Holdings filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
Xtant Medical Holdings Proxy statement: Proxy filing
Xtant Medical Holdings filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
Xtant Medical Holdings Earnings Call Transcript: Q1 2026
Q1 2026 revenue was $20.9M, with a net loss of $3.1M, reflecting divestitures and market headwinds. Full-year revenue guidance was raised to $101M–$105M, driven by new product launches and expanded sales force, with gross margin expected to recover in the second half.
Xtant Medical Holdings Earnings release: Q1 2026
Xtant Medical Holdings released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Xtant Medical Holdings Quarterly report: Q1 2026
Xtant Medical Holdings has published its Q1 2026 quarterly earnings report on May 13, 2026.
Xtant Medical Reports First Quarter 2026 Financial Results
Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bell...
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, ...
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, ...
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont...
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced suppor...
Xtant Medical Holdings Slides: Investor presentation
Xtant Medical Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 6, 2026.
Xtant Medical Holdings Earnings Call Transcript: Q4 2025
Revenue grew 14% in 2025 to $133.9M, with strong gross margin and a return to profitability. 2026 guidance reflects divestitures and non-recurring revenue loss, but core biologics is expected to accelerate as new products and expanded sales force drive growth.
Xtant Medical Holdings Annual report: Q4 2025
Xtant Medical Holdings has published its Q4 2025 annual report on March 31, 2026.
Xtant Medical Holdings Earnings release: Q4 2025
Xtant Medical Holdings released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 3...
Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic condition...
Xtant Medical Holdings Transcript: 2026 CG Musculoskeletal Conference
Strong growth and profitability were driven by vertical integration, product innovation, and strategic divestitures. Expanded product lines and new market entries, including OEM and wound care, support future growth, while a strengthened balance sheet and operational focus position the company for continued success.
Xtant Medical Finalizes Companion Spine Transactions
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xta...
Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...
Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mo...
Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
BELGRADE, Mont. , Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic con...
Xtant Medical Holdings Earnings Call Transcript: Q3 2025
Q3 2025 saw 19% revenue growth to $33.3M, improved gross margin, and a return to profitability, driven by licensing and biologics. Pending sale of non-core assets will enhance liquidity and focus, with 2025 revenue guidance reiterated at $131–$135M.
Xtant Medical Holdings Earnings release: Q3 2025
Xtant Medical Holdings released its Q3 2025 earnings on November 11, 2025, summarizing the period's financial results.
Xtant Medical Holdings Quarterly report: Q3 2025
Xtant Medical Holdings has published its Q3 2025 quarterly earnings report on November 11, 2025.
Xtant Medical Reports Third Quarter 2025 Financial Results
Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Gr...